Emricasan (5 mg)
Sponsors
Conatus Pharmaceuticals Inc.
Conditions
Decompensated CirrhosisFibrosisLiver DiseasesNon-alcoholic Steatohepatitis
Phase 2
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
CompletedNCT02686762
Start: 2016-01-26End: 2019-02-28Updated: 2019-08-19
Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis
NCT03205345
Start: 2017-06-28End: 2019-08-31Target: 210Updated: 2019-03-19